Working together | Boehringer Ingelheim
Working together: We’re built on science, powered by partnerships and grounded in a shared purpose
Curiosity and ideas drive innovation. Whether you’re a biotech or academic, we’re here to explore the unknown with you, pushing the boundaries of what’s possible. To take paths scientifically less travelled. To come up with novel solutions for medical problems.
Our partnering approach is simple
We explore groundbreaking science with people motivated to discover and develop new medicines. Watch the video to learn more about how we approach partnering.
[Our Partnering Interests](/content/partnering/human-health-partnering/partnering-interests "Our Partnering Interests"/index.html)
Ingredients for successful partnerships
The backbone to great research and development is the science and the people behind it. Here’s how we work to bring the best collaborations forward.
Curiosity
We ask bold questions to better understand complex human biology, uncovering what causes diseases and how to treat them.
Creativity
Logic and imagination go together – taking experiments to the next level. We think differently to connect unexpected ideas that push science forward.
Impact
Today we’re helping millions of people live healthier lives. Tomorrow, we want to help even more by turning promising science into real-world solutions.
Types of partnering models
From the earliest stages of research – we’re committed to joining forces with the life science community. Combining knowledge that leads to better treatments.
No two deals are the same. We’re flexible with our partnership models letting our shared vision come to life.
Business structures include:
- Asset and company acquisitions
- Licensing
- Option deal structures
- R&D collaborations
What we look for in partners
A good fit would be if your company / portfolio:
- Aligns with our strategic therapeutic interests
- Complements or expands our pipeline
- Is a first-in-class opportunity with a unique mode of action
- Taps into even more knowledge, cutting-edge tools and emerging trends
Finding novel assets
We’re interested in partnering with you on novel assets from:
- Basic science
- High-risk, high-reward innovations
- Early-stage breakthroughs (from discovery to initial clinical trials)
Collaborating across the life science ecosystem
For certain partnerships, we aim to work with biotechs, academia, and consortiums on the same project. When we bring the life science ecosystem together, we can:
- Take on complex diseases
- Share data
- Make even greater global impact that increases chances of success
We find this useful in areas like artificial intelligence, gene therapy and personalized medicine.
Latest partnerships
[Read more](/content/science-innovation/human-health-innovation/boehringer-licenses-immunitas-novel-antibody-program "Boehringer licenses Immunitas‘ novel antibody program"/index.html)
Boehringer licenses Immunitas‘ novel antibody program
[Read more](/content/science-innovation/human-health-innovation/boehringer-ingelheim-and-zai-lab-announce-collaboration-dll3-targeting-t-cell-engager-and-adc "Testing innovative combinations for small cell lung cancer "/index.html)
Testing innovative combinations for small cell lung cancer
[Read more](/content/science-innovation/human-health-innovation/boehringer-biontech-partnership-advance-sclc-therapy "Advancing new options for small cell lung cancer"/index.html)